Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-01-18
2002-07-02
Siegel, Alan (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S544000, C514S570000, C514S734000, C514S880000
Reexamination Certificate
active
06414017
ABSTRACT:
The invention relates to the inhibition of hair growth.
Arachidonic acid is released from membrane lipids in response to injury or other irritation. The enzyme cyclooxygenase converts arachidonic acid into cyclic endoperoxides commonly known as PGG
2
and PGH
2
. The endoperoxides subsequently are converted into prostoglandins, which are the primary mediators of inflammation in the body.
The enzyme 5-lipoxygenase converts arachidonic acid into 5-hydroperoxyercosa-6,8,11,14-tetraenoic acid, which subsequently is converted into a family of compounds known as leukotrienes. The exact biological role of leukotrienes has not yet been determined.
It has now been found that mammalian (including human) hair growth can be inhibited by applying to the skin a composition including an inhibitor of an enzyme involved in arachidonic acid metabolism in an amount effective to reduce hair growth in the applied area. The inhibitor may, for example, be an inhibitor of cyclooxygenase or lipoxygenase, or may inhibit both enzymes.
Some preferred inhibitors are commonly known as non-steroidal anti-inflammatory drugs (NSAIDs). These drugs include compounds from a variety of chemical classes.
One preferred class of NSAIDs are propionic acids, which include &agr;-methyl-4-[2-methylpropyl]benzeneacetic acid (ibuprofen), 6-methoxy-&agr;-methyl-2-naphthaleneacetic acid (naproxen), 2-[3-phenoxyphenyl]propionic acid (fenoprofen), 2-[3-benzoylphenyl]propionic acid (ketoprofen), gamma-oxo-[1,1′-biphenyl]-4-butanoic acid (fenoprofen), and 6-chloro-&agr;-methylcarbazole-2-acetic acid (carprofen).
Another preferred class of NSAIDs are indoleacetic acids, which include 1-[p-chlorobenzoyl]-5-methoxy-2-methylindole-3-acetic acid (indomethacin), 5-fluoro-2-methyl-1-[(4-(methylsulfinyl)phenyl) methylene]-1H-indene-3-acetic acid (sulindac), 1-methyl-5-[p-toluoyl]pyrrole-2-acetic acid (tolmetin), 2-[(2,6-dichlorophenyl)amino]-benzeneacetic acid (diclofenac).
A third preferred class of NSAIDs are salicylates, which include 2-acetoxybenzoic acid (acetylsalicylic acid) and 5-[2,4-difluorophenyl]salicylic acid (diflunisal).
A fourth preferred class of NSAIDs are anthranilic acids, which include 2-[(2,6-dichloro-3-methylphenyl) amino]benzoic acid (meclofenamic acid) and 2-[(2,3-dimethylphenyl) amino]benzoic acid (mefenamic acid).
A fifth preferred class of NSAIDs are enolic acids, such as 4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide-1,1-dioxide (tenoxicam).
Other NSAIDs like 4-[6-methoxy-2-naphthyl]-2-butanone (nabumetone) also can be used.
Examples of other inhibitors that have been found effective in reducing hair growth include quercetin (3,3′,4′,5,7-pentahydroxy flavone), dl-&agr;-tocopherol, apigenin (4′,5,7-trihydroxy flavone), propyl gallate, NDGA (nordihydroguaiaretic acid), and caffeic acid (3,4-dihydroxycinnamic acid). All of these compounds are known in the art and are commercially available. Other inhibitors are known in the art; see, for example, Laughton et al., 42 Biochemical Pharmacology 1673 (1991).
The composition preferably includes a non-toxic dermatologically, acceptable vehicle or carrier which is adapted to be spread on the skin. Examples of suitable vehicles are acetone, alcohols, or a cream, lotion, or gel which can effectively deliver the active compound. In addition, a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation.
The concentration of the inhibitor in the composition may be varied over a wide range up to a saturated solution, preferably from 1 to 30% by weight or even more; the reduction of hair growth increases as the amount of inhibitor applied increases per unit area of skin. The maximum amount effectively applied is limited only by the rate at which the inhibitor penetrates the skin. Generally, the effective amounts range from 100 to 3000 micrograms or more per square centimeter of skin.
The composition should be applied to the area of the body where it is desired to inhibit hair growth. Typically, the composition can be applied to the face, particularly to the beard area of the face, i.e., the cheek, neck, upper lip, and chin. The composition can also be applied to the legs, arms, torso or armpit. The composition is particularly suitable for the treatment of hirsutism. In humans, the composition should be applied once or twice a day, or even more frequently, for at least three months to achieve a perceived reduction in hair growth.
Reduction of hair growth is demonstrated when the frequency of hair removal is reduced, or the subject perceives less hair on the treated site, or quantitatively, when the weight of hair removed by shaving (i.e., hair mass) is reduced. Male intact Golden Syrian hamsters are considered acceptable models for human beard hair growth in that they display oval shaped flank organs, one on each side, each about 8 mm. in major diameter, which grow thick black and coarse hair similar to human beard hair. These organs produce hair in response to androgens in the hamster.
To evaluate the effectiveness of a particular inhibitor in reducing hair growth, the flank organs of each of a group of hamsters are depilated by applying a thioglycolate based chemical depilatory (Surgex). To one organ of each animal 10 &mgr;l. of vehicle alone once a day is applied, while to the other organ of each animal an equal amount of vehicle containing the inhibitor is applied. After thirteen applications (one application per day for five days a week), the flank organs are shaved and the amount of recovered hair (hair mass) from each is weighed. Percent-reduction of hair growth is calculated by subtracting the hair mass (mg) value of the test compound treated side from the hair mass value of the vehicle treated side; the delta value obtained is then divided by the hair mass value of the vehicle treated side, and the resultant number is multiplied by 100.
REFERENCES:
patent: 3426137 (1969-02-01), Philpitt
patent: 4039669 (1977-08-01), Beyler et al.
patent: 4139638 (1979-02-01), Neri et al.
patent: 4161540 (1979-07-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4269831 (1981-05-01), Ferrari et al.
patent: 4344941 (1982-08-01), Weichert et al.
patent: 4370315 (1983-01-01), Greff et al.
patent: 4439432 (1984-03-01), Peat
patent: 4530844 (1985-07-01), Smerbeck et al.
patent: 4720489 (1988-01-01), Shander
patent: 4877789 (1989-10-01), Shroot
patent: 4885289 (1989-12-01), Breuer et al.
patent: 5095007 (1992-03-01), Ahluwalia
patent: 5096911 (1992-03-01), Ahluwalia et al.
patent: 5132293 (1992-07-01), Shander et al.
patent: 5143925 (1992-09-01), Shander et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5271942 (1993-12-01), Heverhagen
patent: 5300284 (1994-04-01), Wiechers et al.
patent: 5364885 (1994-11-01), Ahluwalia et al.
patent: 5411991 (1995-05-01), Shander et al.
patent: 5928654 (1999-07-01), Duranton
patent: 0 413 528 (1991-02-01), None
patent: 0 532 219 (1993-03-01), None
patent: 0 648 488 (1995-04-01), None
patent: 1 458 349 (1976-12-01), None
patent: 1458349 (1976-12-01), None
patent: 02017115 (1988-07-01), None
patent: 1-96126 (1989-04-01), None
Laughton et al., Inhibition of Mammalian 5-Lipoxygenase and Cyclo-Oxygenase by Flavonoids and Phenolic Dietary Additives, Biochemical Pharmacology, vol. 42, No. 9, pp. 1673-1681, 1991.
Day et al., Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs, Pharmac. Ther. vol. 33, pp. 383-433, 1987.
Database WPI, Week 8441, Derwent Publications Ltd., London, GB, AN 84-254475 and JP A 59 155 314 (Rikagaku Kenkyusho) (Sep. 1984) Abstract.
S.T.N. File Supplier, Karlsruhe, DE, File Chemical Abstracts, vol. 101, n. 2087 (1984).
Goos et al., Arch. Dermatol. Res. (1982) 273:333-341.
Girard et al., Arch. Dermatol. Res. (1980) 269:281-290.
Simpson et al., British Journal of Dermatology (1979) 100, 687.
Sato, The Hair Cycle and its Contol Mechanism, Biology and Disease of the Hair, 3-13 (1975).
Burdick
Ahluwalia Gurpreet S.
Shander Douglas
Siegel Alan
The Gillette Company
LandOfFree
Inhibition of hair growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of hair growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of hair growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2836911